Luye Pharma Group Ltd (F:LUP) — Market Cap & Net Worth
Market Cap & Net Worth: Luye Pharma Group Ltd (LUP)
Luye Pharma Group Ltd (F:LUP) has a market capitalization of $1.05 Billion (€894.77 Million) as of August 5, 2026. Listed on the F stock exchange, this Germany-based company holds position #8606 globally and #1133 in its home market, demonstrating a -2.61% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Luye Pharma Group Ltd's stock price €0.22 by its total outstanding shares 3994515953 (3.99 Billion). See reinvestment intensity of Luye Pharma Group Ltd to understand how much of operating cash flow is reinvested back into capital assets.
Luye Pharma Group Ltd Market Cap History: 2015 to 2026
Luye Pharma Group Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.25 Billion to $1.05 Billion (-6.60% CAGR).
Luye Pharma Group Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Luye Pharma Group Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.22x
Luye Pharma Group Ltd's market cap is 0.22 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.23x
Luye Pharma Group Ltd's market cap is 2.23 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $1.44 Billion | $2.92 Billion | $891.54 Million | 0.49x | 1.61x |
| 2017 | $1.95 Billion | $3.81 Billion | $981.37 Million | 0.51x | 1.99x |
| 2018 | $1.94 Billion | $5.17 Billion | $1.30 Billion | 0.37x | 1.49x |
| 2019 | $2.78 Billion | $6.36 Billion | $1.47 Billion | 0.44x | 1.89x |
| 2020 | $1.59 Billion | $5.54 Billion | $706.59 Million | 0.29x | 2.25x |
| 2021 | $1.82 Billion | $5.20 Billion | -$134.39 Million | 0.35x | N/A |
| 2022 | $2.03 Billion | $5.98 Billion | $604.81 Million | 0.34x | 3.35x |
| 2023 | $1.99 Billion | $6.14 Billion | $532.61 Million | 0.32x | 3.74x |
| 2024 | $1.22 Billion | $6.06 Billion | $471.89 Million | 0.20x | 2.59x |
| 2025 | $1.38 Billion | $6.31 Billion | $618.75 Million | 0.22x | 2.23x |
Competitor Companies of LUP by Market Capitalization
Companies near Luye Pharma Group Ltd in the global market cap rankings as of August 5, 2026.
Key companies related to Luye Pharma Group Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
Luye Pharma Group Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Luye Pharma Group Ltd's market cap moved from $2.25 Billion to $ 1.05 Billion, with a yearly change of -6.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.05 Billion | -24.32% |
| 2025 | €1.38 Billion | +12.98% |
| 2024 | €1.22 Billion | -38.50% |
| 2023 | €1.99 Billion | -1.84% |
| 2022 | €2.03 Billion | +11.28% |
| 2021 | €1.82 Billion | +14.71% |
| 2020 | €1.59 Billion | -42.91% |
| 2019 | €2.78 Billion | +43.38% |
| 2018 | €1.94 Billion | -0.62% |
| 2017 | €1.95 Billion | +35.93% |
| 2016 | €1.44 Billion | -36.10% |
| 2015 | €2.25 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Luye Pharma Group Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.05 Billion USD |
| MoneyControl | $1.05 Billion USD |
| MarketWatch | $1.05 Billion USD |
| marketcap.company | $1.05 Billion USD |
| Reuters | $1.05 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Luye Pharma Group Ltd
Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and X… Read more